|SC 13G/A||amended statement of beneficial ownership||Jul 10, 2014||26.3 KB|
|SC 13G||statement of beneficial ownership||Jul 7, 2014||76.6 KB|
|8-K||current report||Jun 27, 2014||810.0 KB|
|424B5||prospectus filed pursuant to rule 424||Jun 27, 2014||497.9 KB|
|8-K||current report||Jun 26, 2014||27.6 KB|
|FWP||free writing prospectus - filing under securities act rules 163/433||Jun 26, 2014||45.8 KB|
|8-K||current report||Jun 16, 2014||22.9 KB|
|4||jacobs, cindy||Jun 16, 2014||25.9 KB|
|4||cormack, scott daniel||Jun 16, 2014||26.9 KB|
|4||smith, david v||Jun 9, 2014||27.1 KB|
|4||parker, h stewart||Jun 9, 2014||27.1 KB|
|4||mattingly, martin a||Jun 9, 2014||27.1 KB|
|4||goldstein, jack||Jun 9, 2014||27.1 KB|
|4||clendeninn, neil james||Jun 9, 2014||27.1 KB|
|8-K||current report||Jun 2, 2014||27.3 KB|
|10-Q||quarterly report||Apr 30, 2014||419.5 KB|
|8-K||current report||Apr 30, 2014||53.7 KB|
|8-K||current report||Apr 28, 2014||80.4 KB|
|DEF 14A||definitive proxy statement||Apr 24, 2014||565.6 KB|
|4||wyrick, susan d.||Mar 18, 2014||29.0 KB|
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2014 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.